



Transplantation of Glial Cells to Repair Injuries and Diseases of the Nervous System

Guest Editors:

Prof. Dr. James St John

Griffith Institute for Drug
Discovery, Griffith University, 170
Kessels Road Nathan, Brisbane,
QLD 4111, Australia

Dr. Mo Chen

Menzies Health Institute
Queensland, Griffith University,
University Drive, Southport, QLD
4222, Australia

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

The transplantation of glial cells to repair injuries and diseases of the nervous system is a growing field, and many promising outcomes have been demonstrated in various injury models. For example, various types of glial cells have been tested in pre-clinical and clinical trials to repair spinal cord injury, peripheral nerve injury including optic nerve and brachial plexus injuries, and brain injury, and to treat demyelinating diseases and neurodegeneration.

This Special Issue seeks original research articles and reviews that address the latest approaches used for glial cell transplantation. Topics can include, but are not limited to, glial cell transplantation that involves new cell-preparation technologies; methods to improve cell survival after transplantation; timing and method of transplantation; and motor, sensory and autonomic tests to determine functional outcomes. By gathering these submissions into one Special Issue, we aim to promote new ideas that can be adopted by others to improve outcomes for a range of neural therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Jessica Filosa

Department of Physiology,
Augusta University, Augusta, GA
30912, USA

Message from the Editor-in-Chief

Neuroglia covers the critically important functions of the diverse range of cells within the nervous system that are collectively called glia. Our journal focuses on the development, function, and pathology of glia in the central and peripheral nervous systems, as well as how these cells can be used therapeutically to repair injuries and diseases of the nervous system. The journal welcomes research using the latest in vitro and in vivo animal and human research, with a view to its translation into potential human therapies.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **ESCI (Web of Science)**, **Scopus** and **other databases**.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.5 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the first half of 2025).

Contact Us

Neuroglia Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/neuroglia
neuroglia@mdpi.com
[X@Neuroglia_MDPI](https://twitter.com/Neuroglia_MDPI)